Trial reportEuropean journal of nuclear medicine and molecular imaging2011
PET/CT and 3-T whole-body MRI in the detection of malignancy in treated oropharyngeal and hypopharyngeal carcinoma.
Trial report in European journal of nuclear medicine and molecular imaging, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- FDG-PET/CT for treatment response assessment in head and neck squamous cell carcinoma: a systematic review and meta-analysis of diagnostic performance.European journal of nuclear medicine and molecular imaging · 2018Pooled it
- PET Imaging in Head and Neck Squamous Cell Carcinoma: from Staging to Response Assessment.Current oncology reports · 2026Review
- Positron Emission Tomography-Magnetic Resonance Imaging, a New Hybrid Imaging Modality for Dentomaxillofacial Malignancies-A Systematic Review.Diagnostics (Basel, Switzerland) · 2025Review
- Review
- Prognostic value of 18F-FDG PET/MRI in patients with advanced oropharyngeal and hypopharyngeal squamous cell carcinoma.Annals of nuclear medicine · 2021Article
- Comparison ofEuropean journal of nuclear medicine and molecular imaging · 2020Article
- Use of PET in Head and Neck Cancers.Turkish archives of otorhinolaryngology · 2015Review
- Article
- Comparison between whole-body MRI and Fluorine-18-Fluorodeoxyglucose PET or PET/CT in oncology: a systematic review.Radiology and oncology · 2013Review
- Evaluation of whole-body MR to CT deformable image registration.Journal of applied clinical medical physics · 2013Article
- Sequential whole-body PET/MR scanner: concept, clinical use, and optimisation after two years in the clinic. The manufacturer's perspective.Magma (New York, N.Y.) · 2013Review
- Prognostic value of pretreatment ¹⁸F-FDG PET/CT and human papillomavirus type 16 testing in locally advanced oropharyngeal squamous cell carcinoma.European journal of nuclear medicine and molecular imaging · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe performed a prospective comparison of the diagnostic capability of integrated fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) (PET/CT), 3-T whole-body magnetic resonance imaging (WB-MRI) and their combination in detecting malignancy in treated oropharyngeal or hypopharyngeal squamous cell carcinoma (OHSCC).
methodsSeventy-nine OHSCC patients at a high risk of residual disease or suspected to have recurrence after the completion of chemoradiation were included in the study. All patients underwent PET/CT and WB-MRI within 10 days of each other. Histology and follow-up data were used as the reference standard. The McNemar test was used to compare sensitivity and specificity, while the area under the receiver-operating characteristic curve (AUC) was used for comparison of diagnostic capabilities.
resultsTwenty-nine patients (36.7%) had residual/recurrent tumours or second primary tumours. Overall, there was a trend towards increased sensitivity and diagnostic capability for PET/CT compared with WB-MRI (72.4 vs 55.2%, p = 0.13; 0.826 vs 0.753, p = 0.24, respectively). The diagnostic capability of combined interpretation of PET/CT and WB-MRI was similar to PET/CT alone (0.827 vs 0.826, p = 0.97) but was significantly higher than WB-MRI alone (0.827 vs 0.753, p = 0.04).
conclusionPET/CT showed a trend towards higher diagnostic capability than 3-T WB-MRI in detecting residual/recurrent tumours or second primary tumours in OHSCC. The combined use of PET/CT and WB-MRI provided more added value to WB-MRI alone than to PET/CT alone. Additional PET/CT can be useful in patients with questionable MRI findings of malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.